CoChat

Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction

Open access
Stähli, Barbara E., Varbella, Ferdinando, Linke, Axel, Schwarz, Bettina, Felix, Stephan B., Seiffert, Moritz, Kesterke, Rahel, Nordbeck, Peter, Witzenbichler, Bernhard, Lang, Irene M., Kessler, Mirjam, Valina, Christian, Dibra, Alban, Rohla, Miklos, Moccetti, Marco, Vercellino, Matteo, Gaede, Luise, Bott-Flügel, Lorenz, Jakob, Philipp, Stehli, Julia, Candreva, Alessandro, Templin, Christian, Schindler, Matthias, Wischnewsky, Manfred, Zanda, Greca, Quadri, Giorgio, Mangner, Norman, Toma, Aurel, Magnani, Giulia, Clemmensen, Peter, Lüscher, Thomas F., Münzel, Thomas, Schulze, P. Christian, Laugwitz, Karl-Ludwig, Rottbauer, Wolfgang, Huber, Kurt, Neumann, Franz-Josef, Schneider, Steffen, Weidinger, Franz, Achenbach, Stephan, Richardt, Gert, Kastrati, Adnan, Ford, Ian, Maier, Willibald, Ruschitzka, Frank · 2023 · New England Journal of Medicine
Cited by 188

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease, the time at which complete revascularization of nonculprit lesions should be performed remains unknown. METHODS: We performed an international, open-label, randomized, noninferiority trial at 37 sites in Europe. Patients in a hemodynamically stable condition who had STEMI and multivessel coronary artery disease were randomly assigned to undergo immediate multivessel percutaneous coronary intervention (PCI; immediate group) or PCI of the culprit lesion followed by staged multivessel PCI of nonculprit lesions within 19 to 45 days after the index procedure (staged group). The primary end point was a composite of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year after randomization. The percentages of patients with a primary or secondary end-point event are provided as Kaplan-Meier estimates at 6 months and at 1 year. RESULTS: We assigned 418 patients to undergo immediate multivessel PCI and 422 to undergo staged multivessel PCI. A primary end-point event occurred in 35 patients (8.5%) in the immediate group as compared with 68 patients (16.3%) in the staged group (risk ratio, 0.52; 95% confidence interval, 0.38 to 0.72; P<0.001 for noninferiority and P<0.001 for superiority). Nonfatal myocardial infarction and unplanned ischemia-driven revascularization occurred in 8 patients (2.0%) and 17 patients (4.1%), respectively, in the immediate group and in 22 patients (5.3%) and 39 patients (9.3%), respectively, in the staged group. The risk of death from any cause, the risk of stroke, and the risk of hospitalization for heart failure appeared to be similar in the two groups. A total of 104 patients in the immediate group and 145 patients in the staged group had a serious adverse event. CONCLUSIONS: Among patients in hemodynamically stable condition with STEMI and multivessel coronary artery disease, immediate multivessel PCI was noninferior to staged multivessel PCI with respect to the risk of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year. (Supported by Boston Scientific; MULTISTARS AMI ClinicalTrials.gov number, NCT03135275.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2307823

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Stähli, B. E., Varbella, F., Linke, A., Schwarz, B., Felix, S. B., Seiffert, M., Kesterke, R., Nordbeck, P., Witzenbichler, B., Lang, I. M., Kessler, M., Valina, C., Dibra, A., Rohla, M., Moccetti, M., Vercellino, M., Gaede, L., Bott-Flügel, L., Jakob, P., Stehli, J., Candreva, A., Templin, C., Schindler, M., Wischnewsky, M., Zanda, G., Quadri, G., Mangner, N., Toma, A., Magnani, G., Clemmensen, P., Lüscher, T. F., Münzel, T., Schulze, P. C., Laugwitz, K.-L., Rottbauer, W., Huber, K., Neumann, F.-J., Schneider, S., Weidinger, F., Achenbach, S., Richardt, G., Kastrati, A., Ford, I., Maier, W., & Ruschitzka, F.
Venue
New England Journal of Medicine
Published
2023-10-12
Volume
389
Issue
15
Pages
1368-1379
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4386205985
Cited by
188
References
4
FWCI
44.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.